{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:06:41Z","timestamp":1793844401259,"version":"4.6.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ekir.2023.10.023","type":"journal-article","created":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T16:27:44Z","timestamp":1699028864000},"page":"134-144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence"],"prefix":"10.1016","volume":"9","author":[{"given":"Alexandre","family":"Destere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Teisseyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Cremoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre O","family":"G\u00e9rard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Crepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Jourde-Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Gra\u00e7a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Brglez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Benzaken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent L.M.","family":"Esnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Seitz-Polski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.10.023_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.023_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.10.023_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.10.023_bib4","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.023_bib5","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2023.10.023_bib6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.ekir.2023.10.023_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.10.023_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.10.023_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.10.023_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.10.023_bib11","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/ndt\/gfz041","article-title":"Rituximab bioavailability in primary membranous nephropathy","volume":"34","author":"Boyer-Suavet","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.10.023_bib12","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.10.023_bib13","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.023_bib14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/1060028018803587","article-title":"Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy","volume":"53","author":"Fogueri","year":"2019","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ekir.2023.10.023_bib15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2023.10.023_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdf155","article-title":"Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study","volume":"13","author":"Igarashi","year":"2002","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2023.10.023_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10928-022-09802-2","article-title":"Application of machine learning based methods in exposure-response analysis","volume":"49","author":"Liu","year":"2022","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.ekir.2023.10.023_bib18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/RHU.0000000000001688","article-title":"Defining a therapeutic window for rituximab maintenance therapy in ANCA-associated vasculitis: a longitudinal observational study","volume":"27","author":"Springer","year":"2021","journal-title":"J\u00a0Clin Rheumatol"},{"key":"10.1016\/j.ekir.2023.10.023_bib19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.023_bib20","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.11791018","article-title":"High-dose rituximab and early remission in PLA2R1-related membranous nephropathy","volume":"14","author":"Seitz-Polski","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.023_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.kint.2018.08.045","article-title":"Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody","volume":"95","author":"Dahan","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.10.023_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cell.2020.03.022","article-title":"How machine learning will transform biomedicine","volume":"181","author":"Goecks","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ekir.2023.10.023_bib23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40262-022-01138-x","article-title":"A\u00a0hybrid model associating population pharmacokinetics with machine learning: a case study with iohexol clearance estimation","volume":"61","author":"Destere","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2023.10.023_bib24","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s11095-022-03351-6","article-title":"Optimization of vancomycin initial dose in term and preterm neonates by machine learning","volume":"39","author":"Ponthier","year":"2022","journal-title":"Pharm Res"},{"key":"10.1016\/j.ekir.2023.10.023_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40262-020-00927-6","article-title":"A\u00a0machine learning approach to estimate the glomerular filtration rate in intensive care unit patients based on plasma iohexol concentrations and covariates","volume":"60","author":"Woillard","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2023.10.023_bib27","author":"Kuhn"},{"key":"10.1016\/j.ekir.2023.10.023_bib28","author":"Kuhn"},{"key":"10.1016\/j.ekir.2023.10.023_bib29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/NT.0000000000000092","article-title":"Body mass index: obesity, BMI, and health: a critical review","volume":"50","author":"Nuttall","year":"2015","journal-title":"Nutr Today"},{"key":"10.1016\/j.ekir.2023.10.023_bib30","article-title":"Simplified calculation of body-surface area","volume":"317","author":"Mosteller","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.10.023_bib31","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/bcp.13271","article-title":"Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome: pharmacokinetics of rituximab and clinical outcome","volume":"83","author":"Rozman","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2023.10.023_bib32","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1177\/0091270005277075","article-title":"Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a Phase II clinical trial","volume":"45","author":"Ng","year":"2005","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2023.10.023_bib33","first-page":"1129","article-title":"Nephrotic syndrome in adults: diagnosis and management","volume":"80","author":"Kodner","year":"2009","journal-title":"Am Fam Phys"},{"key":"10.1016\/j.ekir.2023.10.023_bib34","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.2215\/CJN.07210810","article-title":"Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy","volume":"6","author":"Hofstra","year":"2011","journal-title":"CJASN"},{"key":"10.1016\/j.ekir.2023.10.023_bib35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2012030242","article-title":"Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy","volume":"23","author":"Hofstra","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.10.023_bib36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/ckj\/sfw121","article-title":"Anti-phospholipase A2 receptor antibody levels at diagnosis predicts spontaneous remission of idiopathic membranous nephropathy","volume":"10","author":"Jullien","year":"2017","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2023.10.023_bib37","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40262-019-00826-5","article-title":"Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis: the RAVE trial revisited","volume":"59","author":"Bensalem","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ekir.2023.10.023_bib38","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1177\/0091270011430506","article-title":"Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia","volume":"52","author":"Li","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.ekir.2023.10.023_bib39","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1472-8206.2009.00714.x","article-title":"Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma","volume":"23","author":"Blasco","year":"2009","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ekir.2023.10.023_bib40","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/psp4.12665","article-title":"Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia","volume":"10","author":"Gibiansky","year":"2021","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"key":"10.1016\/j.ekir.2023.10.023_bib41","article-title":"Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923015632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923015632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:46:30Z","timestamp":1762832790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923015632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2468024923015632"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.10.023","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.11.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}